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INTRODUCTION
Ischemic stroke is the second leading cause of death worldwide 
accompanied by severe disability [1]. Cerebral ischemia and 
reperfusion injury leads to damage of brain tissues, inflammation 
as a result of the blood–brain barrier (BBB) disruption, oxidative 
damage [2], and apoptosis [3]. Brain tissue is highly vulnerable 
to oxidative damage because of its high use of oxygen [4] under 
cerebral ischemia. Cerebral ischemia leads to loss of  tight 
junction proteins in brain endothelium, BBB disruption, and 
finally brain edema [5]. Brain edema leads to an imbalance in 
energy demand and influences on the postsynaptic effects of 
glutamate [6] and interruption of synaptic transmission in the 
penumbra after stroke [7,8]. Overall, excitotoxicity, inflammation 
and oxidative stress caused by ischemic stroke plays a crucial 
role in the pathophysiology of ischemic stroke [9,10]. To reduce 
the brain damage caused by cerebral ischemia, the solution for 
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oxidative damage is the issue of the greatest importance. Vitamin 
C is the most important antioxidant for metabolic function 
of the brain [11-13] owing to its low redox potential which is 
capable of neutralizing diverse pro oxidants [14-17]. Mainly, 
vitamin C could be found in its form such as ascorbic acid (AA) 
and dehydroascorbic acid (DHA) (AA’s oxidized form) [18,19]. 
According to earlier studies, lower levels of vitamin C are a risk 
factor of cerebral stroke [20,21] and actually, decreased vitamin C 
levels has been demonstrated in patients with ischemic stroke [22]. 
Recent study demonstrated that the treatment of AA prevented 
the disruption of BBB and sustained the BBB integrity in the 
cortex [23]. Neuroprotection by DHA has been demonstrated in 
several recent studies in both in vitro and in vivo. In in vitro study, 
DHA has been reported that it inhibits mitochondrial damage and 
cell death against oxidative injury [24]. Specifically, DHA among 
vitamin C could crosses the BBB through glucose transporter 1 
(GLUT1) [25] and prevents cell death against oxidative damage by 
increasing glutathione (GSH) levels through glucose transporters 
[26,27]. In in vivo  study, DHA have been reported to have 
protective effects as antioxidants in experimental neurological 
disease models such as stroke [19,28-30]. DHA administration 
attenuates oxidative stress markers and inflammation in 
hyperglycemic stroke models [31]. However, the study on the role 
of DHA administration through intra-peritoneal route in ischemic 
stroke animal model focused on edema formation, neurotoxicity, 
and synaptic dysfunction has not yet been determined. In present 
study, we investigated DHA’s beneficial effect after ischemic brain 
injury in in vivo  study. Our results show that DHA is involved 
in the prevention of brain edema formation, neurotoxicity, and 
synaptic dysfunction following ischemia injury. Thus, we suggest 
that DHA might mitigate stroke-induced pathological alterations 
following cerebral ischemic stroke.
MATERIALS AND METHODS
Animal model
Male Sprague-Dawley (SD) rat (Orient, GyeongGi-Do, Korea; 
8 weeks old; 250-260 g) were subjected to transient focal cerebral 
ischemia by intraluminal middle cerebral artery blockade with a 
nylon suture, as previously described [32]. After 60 min of middle 
cerebral artery occlusion (MCAO), blood flow was restored by 
withdrawing the suture, and regional cerebral blood flow was 
monitored using a laser Doppler flow meter (Transonic Systems, 
Inc., Ithaca, NY, USA). All animal procedures and experiments 
were performed in accordance with the Guide to the Care and Use 
of Laboratory Animals and were approved by the Association for 
Assessment and Accreditation of Laboratory Animal Care.
Drug treatments
For each experiment, rats were given anesthesia (chloral hydrate 
300 mg/kg,ip). DHA was purchased from Sigma (Sigma-Aldrich, 
St. Louis, MO, USA), and dissolved in normal saline (pH 7.5) and 
administered to rat through intra-peritoneal (i.p) route. Rats were 
injected with DHA (100 mg/kg/ml) treatment at a time for 10 min 
just after MCAO occlusion time. Control animals were given an 
equal volume of saline by the same procedure.
Evaluation of brain edema
For the evaluation of brain edema, mice were sacrificed at 
reperfusion 24 hr after MCAO injury. Brain slices (2 mm thick) 
between 22.00 mm and +4.00 mm from Bregma were incubated 
with 2% 2, 3, 5-triphenyltetraxolium chloride (TTC) (Sigma-
Aldrich, St. Louis, MO, USA) at 37°C for 10 min in the dark in a 
drying oven, and later photographed using a Nikon E950 digital 
camera attached to a dissecting microscope. Infarct volume 
was determined from digitized images using the Quantity One 
software package (Bio-Rad, CA, USA). Typically 3 such slices were 
used for analysis. The area of the cortical and striatal infarct was 
measured separately in all slices in the ischemic and non-ischemic 
hemisphere. The ipsilateral and contralateral hemispheres were 
used to calculate the percentage of brain edema [33].
Brain edema (%) =
                                                                     
                                  
 Ⅹ 100 
Cresyl violet staining
At reperfusion 24 hr after MCAO injury, mice were sacrificed 
and brains were fixed in 3.7% formaldehyde and quickly frozen. 
Tissues were sectioned coronally at 20 µm thickness and 
sequentially dipped into xylene 5 min, 100% alcohol 5 min, 95% 
alcohol 5 min, and 70% alcohol 5 min. Samples were stained with 
cresyl violet (Sigma-Aldrich, St. Louis, MO, USA) for 3 min. After 
the staining, slides were reacted with 70% alcohol 5 min, 95% 
alcohol 5 min, 100% alcohol 5 min, and xylene 5 min. After these 
processes, sections were observed under a microscope equipped 
with a digital camera (Olympus, Tokyo, Japan).
Western blot analysis
At reperfusion 24 hr after MCAO injury, rat were sacrificed 
and brains were washed rapidly with ice-cold PBS, and collected. 
Tissues were lysed with ice-cold RIPA buffer (Sigma-Aldrich, St. 
Louis, MO, USA). The lysates were centrifuged at 13,200 rpm for 
1 hr at 4°C to produce whole-cell extracts. Protein content was 
quantified using the BCA method (Pierce, Rockford, IL, USA). 
Protein (20 μg) was separated on a 10% SDS–polyacrylamide 
(PAGE) gel and transferred onto a polyvinylidene difluoride 
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(PVDF) membrane. After blocking with 5% bovine serum 
albumin, prepared in Tris-buffered saline/Tween (TBS-T; 20 nM 
Tris [pH 7.2], 150 mM NaCl, and 0.1% Tween 20), for 1hr at room 
temperature (RT), immunoblots were incubated overnight at 4°C 
with primary antibodies that specifically detect Bcl 2 associated 
X protein (Bax) (1:1000, Abcam, Cambridge, MA, USA), Cleaved 
caspase-3 (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), or β-actin (1:2000, Cell Signaling Technology, Danvers, MA, 
USA). Next, blots were incubated with HRP-linked anti-mouse 
and -rabbit IgG antibodies purchased from Abcam (Cambridge, 
UK) for 1 hr at RT. Enhanced chemiluminescence was performed 
by ECL (Pierce) [34].
Immunohistochemistry 
Five-micrometer-thick frozen brain sections were cut onto clean 
glass slides (Thermo Scientific, Waltham, MA, USA), air-dried, 
and fixed in cold acetone for 10 min at -20°C. The slides were 
first washed in Tris-buffered saline (TBS) and then incubated 
with 0.3% H2O2 in methanol to quench endogenous peroxidase 
activity. Followed by a series of washes (three times with distilled 
water), the sections were blocked with 10% normal rabbit serum. 
Frozen brain sections (20 μm) were fixed in ice-cold acetone for 
20 min. To block nonspecific labeling, sections were incubated in 
5% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO, 
USA) diluted in PBS for 30 min before addition of primary and 
secondary antibodies. Primary antibodies for aquaporin-1 (AQP-
1) (1:50, Abcam, Cambridge, MA, USA), inducible nitric oxide 
synthase (iNOS) (1:50, Millipore, Billerica, MA, USA), Bax (1:200, 
Abcam, Cambridge, MA, USA), Cleaved caspase-3 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), Claudin 5 (1:50, Invitrogen, 
Carlsbad, CA, USA), postsynaptic density protein-95 (PSD-95) 
(1:50, Abcam, Cambridge, MA, USA) were applied to the samples 
for 24 hr at 4°C, followed by a 90 min incubation with appropriate 
florescence secondary antibody (1:100, Invitrogen, Carlsbad, 
CA, USA) and three washes in PBS for 10 min each. After three 
washes in 0.1% PBS with Tween-20 (PBST), the sections were 
incubated with rhodamine-conjugated sheep anti-rabbit or FITC-
conjugated sheep anti-mouse secondary antibody that was diluted 
to 1:200 with 5% BSA fraction V in 0.1% PBST for 2 hr in the 
dark at RT. After three washes in PBS, all sections were incubated 
with 1 μg/mL of 4',6-diamidino-2-phenylindole (Sigma-Aldrich, 
St. Louis, MO, USA) and 2 μg/mL of propidium iodide (Sigma-
Aldrich, St. Louis, MO, USA) for a counter staining. Tissues were 
then visualized under a confocal microscope (Zeiss LSM 700, 
Carl Zeiss, Oberkochen, Germany). Positive cells percentage were 
measured by using Image J as following the previous study [35].
Statistical analysis
Statistical analyses were carried out using SPSS 18.0 software 
(IBM Corp., Armonk, NY, USA). All data are expressed as mean± 
S.E.M. Significant intergroup differences were determined by one-
way analysis of variance followed by Bonferroni post hoc multiple 
comparison test. Statistical significance with the MCAO group 
(experimental control (EC) group) was determined by t-test. Each 
experiment conducted 3 replicates per condition. Differences were 
considered significant at *p < 0.05, **p < 0.01.
RESULTS
DHA reduced brain edema formation following cerebral 
ischemia
To investigate whether DHA affects vascular permeability in 
animal brain, we measured brain edema at reperfusion 24 hr after 
MCAO injury using TTC staining (Fig. 1A). White areas in brain 
are damaged brain areas due to ischemia (Fig. 1A). Fig. 1B shows 
the infarct size of brain in both groups (Fig. 1B). The graph shows 
the percentage of the ipsilateral hemisphere compared with the 
contralateral hemisphere both in the MCAO and DHA groups 
(Fig. 1C). The percentage of brain edema in the MCAO group was 
>12% whereas the percentage of brain edema after DHA treatment 
was <8% (Fig. 1C). Brain edema (%) was significantly reduced in 
the DHA group compared with the MCAO group. Our results 
indicate that the DHA treatment reduced brain edema formation 
after ischemic brain injury. 
DHA reduced the expression of AQP-1 as the marker of 
vascular permeability following cerebral ischemia 
We performed immunohistochemistry using AQP-1 antibody 
at reperfusion 24 hr after MCAO injury to examine whether there 
were change of markers that affect vascular permeability both 
in cortex (Fig. 2A) and in striatum (Fig. 2B). We did not observe 
AQP-1 immunoreactivity in the cortex of the normal control 
(NC) group (Fig. 2A). However, AQP-1 positive cells were strongly 
expressed in the cortex in reperfusion 24hr after MCAO injury 
group (experimental control (EC) group) (Fig. 2A). In addition, 
DHA treated MCAO rat brain did not exhibit strongly the 
expression of AQP-1 compared to 24hr MCAO group (EC group). 
In striatum, AQP-1 expression showed the same pattern as the 
cortex (Fig. 2B). In addition, the water channel molecule AQP-1 
was detected in rat brain cortex and striatum at 24 hr after MCAO 
injury (Fig. 2). Fig. 2C was significantly shown the decreased 
fluorescent intensity of AQP-1 over 3 times in the DHA treatment 
group compared to EC group (Fig. 2C). These data indicate that 
DHA affects the expression of AQP-1 in ischemic brain and may 
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be involved in vascular permeability and edema after ischemia. 
DHA protects blood brain barrier (BBB) disruption following 
cerebral ischemia
We conducted immunohistochemistry using Claudin 5 antibody 
at reperfusion 24 hr after MCAO injury to confirm whether or not 
there was change of marker as the component junction protein of 
blood brain barrier (BBB) both in cortex (Fig. 3A) and in striatum 
(Fig. 3B). In the NC group, Claudin 5 was considerably expressed 
both in cortex (Fig. 3A) and in striatum (Fig. 3B). However, 
Claudin 5 expression was evidently attenuated both in cortex (Fig. 
3A) and in striatum (Fig. 3B) at reperfusion 24hr after MCAO 
injury group (EC group) (Fig. 3A). In the DHA treatment group, 
Claudin 5 expression was more increased both in cortex (Fig. 
3A) and in striatum (Fig. 3B) compared to EC group. Fig. 3C was 
shown the significantly increased fluorescent intensity of Claudin 
5 over 2 times in the DHA treatment group compared to EC 
group (Fig. 3C). Based on these results, we suggest that DHA may 
Fig. 1. Measurement of edema for ma tion in MCAO mouse brain at reper fu sion 24 hr after MCAO injury. (A) At reperfusion 24 hr after MCAO injury, 
TTC staining showed that white areas were damaged by ischemic injury. White areas reduced in the DHA treatment group compared to experimental 
control (EC) group. (B) Infarct size (%) was mea sured at reperfusion 24 hr after MCAO injury. The graph shows the infarct size was significantly 
attenuated in DHA treatment group. (C) The graph shows that brain edema (%) was significantly reduced in DHA treatment group com pared with EC 
group. Differences were considered significant at *p<0.05. **p<0.0 (t-test via EC group). EC: reper fusion 24 hr after MCAO injury, DHA: DHA treatment 
and reperfusion 24 hr after MCAO injury.
Fig. 2. Immunochemical image for measurement of AQP-1 expression by DHA treatment. (A) Immunochemical images showed that in DHA 
treatment group, AQP-1 positive cells (green) was decreased in rat cortex, compared with the EC group. (B) In DHA treated ischemic striatum, AQP-
1’s expression was decreased in striatum owing to DHA treatment. (C) The graph showed the percentage (%) of AQP-1 positive cells to compare the 
difference of AQP-1 fluorescence intensity between EC group and DHA group. Differences were considered significant at *p<0.05 (t-test via EC group). 
Scale bar=100 μm, AQP-1: aquaporin 1 (AQP-1); green, 4', 6-diamidino-2-phenylindole (DAPI): blue. NC: normal control group, EC: experimental 
control; reperfusion 24 hr after MCAO injury, DHA: DHA treatment and reperfusion 24 hr after MCAO injury.
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preserve the expression of Claudin 5 in ischemic brain and also 
protect the BBB disruption. 
Morphological alteration assessment using cresyl violet 
staining by DHA treatment
Cresyl violet staining was performed at reperfusion 24 hr after 
MCAO injury to assess the extent of ischemia-induced damage 
histologically in the striatum and cortex (Fig. 4). In the normal 
control group (without MCAO injury, without DHA treatment), 
intact cellular structure was observed in both the cortex and 
striatum. In the MCAO group (EC group), shrinked small cell 
bodies were detected, and also damaged tissue was observed in the 
ischemic cortex and striatum (Fig. 4). In DHA group treatment 
(DHA treatment and MCAO injury), damaged cells were reduced 
in number compared with EC group, and we observed healthy 
round cells in the ischemic cortex and striatum (Fig. 4). 
DHA attenuates the cell damage against neurotoxicity 
following cerebral ischemia 
We performed immunohistochemical staining using cleaved 
Fig. 3. Immunochemical image for confirmation of preserved Claudin 5 expression by DHA treatment. (A) Immunochemical images showed 
that Claudin 5-positive cells (green) were obviously reduced in rat cortex of experimental control (EC) group whereas in DHA treatment group, its 
expression was preserved in cortex. (B) Claudin 5-positive cells were retained in rat striatum owing to DHA treatment. (C) The graph showed the 
percentage (%) of Claudin 5 positive cells to compare the difference of Claudin 5 fluorescence intensity. Differences were considered significant at 
*p<0.05 (t -test via EC group). Scale bar=100 μm, Claudin 5: green, 4', 6-diamidino-2-phenylindole (DAPI): blue. NC: normal control group, EC: 
experimental control; reperfusion 24 hr after MCAO injury, DHA: DHA treatment and reperfusion 24 hr after MCAO injury.
Fig. 4. The histological assessment using cresyl violet staining after ischemic injury. Atlas of rat brain mainly presents the corpus callosum, cerebral 
cortex (a) and striatum (b). Cresyl violet staining indicated that severe cell loss was founded in the 24 hr MCAO group whereas more healthy and 
round cell bodies in striatum and cortex were observed in MCAO with DHA treatment group. a: cortex, b: striatum, NC: normal control group, EC: 
experimental control; reperfusion 24 hr after MCAO injury, DHA: DHA treatment and reperfusion 24 hr after MCAO injury.
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caspase-3 antibody at reperfusion 24 hr after MCAO injury 
to examine whether DHA influences on the cell death both in 
cortex (Fig. 5A) and in striatum (Fig. 5B). Cleaved caspase-3 
immunopositive cells were not observed in the rat cortex of 
the normal control (NC) group (Fig. 5A). However, cleaved 
caspase-3 positive cells were strongly expressed in the cortex in 
reperfusion 24 hr after MCAO injury group (EC group) (Fig. 5A). 
In addition, DHA treated rat cortex did not exhibit the expression 
of cleaved caspase-3 strongly compared to 24 hr MCAO group 
(EC group) (Fig. 5A). In striatum, cleaved caspase-3 expression 
showed the same pattern of the cortex (Fig. 5B). Fig. 5C was 
shown that the fluorescent intensity of cleaved caspase-3 was 
attenuated significantly over 4 times in the DHA treatment group 
compared to EC group (Fig. 5C). The western blot data (Fig.5D) 
also showed the reduction of cleaved caspase-3 expression in the 
DHA treatment group in spite of the MCAO injury. Following 
these data, DHA may inhibit the cell death under ischemic injury 
by attenuating the expression of cleaved caspase-3. Second, 
Fig. 5. Immunochemical image for confirmation of reduced cleaved caspase-3 expression by DHA treatment. (A) Immunochemical images showed 
that cleaved caspase-3 positive cells (red) were densely expressed in the EC group. In DHA treatment group, cleaved caspase-3 expression was decreased 
in rat cortex, compared with the EC group. (B) In DHA treatment group, cleaved caspase-3 positive cells were decreased in rat striatum due to DHA 
treatment. (C) The graph showed the percentage (%) of cleaved caspase-3 positive cells to compare the difference of cleaved caspase-3 fluorescence 
intensity. Statistical significance with EC group was determined by t-test. (D) The graph of cleaved caspase-3 protein level showed the same pattern 
with immunochemical images. Differences were considered significant at *p<0.05, (ANOVA followed by Bonferroni post hoc  multiple comparison 
test). Scale bar=100 μm, Cleaved caspase-3: red, 4', 6-diamidino-2-phenylindole (DAPI): blue. NC: normal control group, EC: experimental control; 
reperfusion 24 hr after MCAO injury, DHA: DHA treatment and reperfusion 24 hr after MCAO injury.
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we conducted immunohistochemistry using Bax antibody at 
reperfusion 24 hr after MCAO injury to examine whether DHA 
influences on the alteration of marker that affects mitochondrial 
cell death both in cortex (Fig. 6A) and in striatum (Fig. 6B). We 
did not observe Bax immunoreactivity in the rat cortex of the 
normal control (NC) group (Fig. 6A). However, the expression 
of Bax was increased strongly in the cortex at reperfusion 24 hr 
after MCAO injury group (EC group) (Fig. 6A). In addition, the 
expression of Bax were not strongly exhibited in the cortex of 
DHA treated MCAO group compared to 24 hr MCAO group 
Fig. 6. Immunochemical image for confirmation of reduced Bax expression by DHA treatment. (A) Immunochemical images showed that Bax positive 
cells (red) were densely expressed in the EC group. In DHA treatment group, Bax expression was decreased in rat cortex, compared with the EC group. 
(B) In DHA treatment group, Bax positive cells were decreased in rat striatum due to DHA treatment. (C) The graph showed the percentage (%) of Bax 
positive cells to compare the difference of Bax fluorescence intensity. Statistical significance with EC group was determined by t-test. (D) The graph 
of Bax protein level showed the same pattern with immunochemical images. Differences were considered significant at *p<0.05, **p<0.01 (ANOVA 
followed by Bonferroni post hoc  multiple comparison test). Scale bar=100 μm, Bax: bcl2 associated X protein (Bax); red, 4', 6-diamidino-2-phenylindole 
(DAPI): blue. NC: normal control group, EC: experimental control; reperfusion 24 hr after MCAO injury, DHA: DHA treatment and reperfusion 24 hr 
after MCAO injury.
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(EC group) (Fig. 6A). In striatum, Bax expression showed the 
same pattern as the cortex (Fig. 6B). Fig. 6C was shown that the 
significantly reduced fluorescent intensity of Bax over 2 times 
in the DHA treatment group compared to EC group (Fig. 6C). 
The western blot data (Fig. 6D) also showed the reduction of Bax 
expression in the DHA treatment group compared to the MCAO 
injury (Fig. 6D). Considering these data, DHA may influence on 
the cellular protection against the mitochondrial cell death under 
ischemic injury by attenuating the expression of Bax. Additionally, 
we conducted immunohistochemistry using iNOS antibody at 
reperfusion 24 hr after MCAO injury to confirm whether there 
was change of marker as the inflammatory mediator in both 
cortex (Fig. 7A) and striatum (Fig. 7B) or not. In the EC group, 
iNOS was considerably expressed in both in cortex (Fig. 7A) and 
striatum (Fig. 7B). However, iNOS expression was not found in 
both cortex (Fig. 7A) and striatum (Fig. 7B) at NC group. In the 
Fig. 7. Immunochemical image for confirmation of attenuated iNOS expression by DHA treatment. (A) Immunochemical images showed that iNOS 
positive cells (red) were considerably expressed in the EC group. The rat cortex in DHA treatment group showed reduced iNOS expression compared 
with EC group. (B) In DHA treatment group, iNOS positive cells were decreased in rat striatum. (C) The graph showed the percentage (%) of iNOS 
positive cells to compare the difference of iNOS fluorescence intensity. Differences were considered significant at **p<0.01 (t -test via EC group). 
Scale bar=100 μm, iNOS: inducible nitric oxide synthase (iNOS); red, 4', 6-diamidino-2-phenylindole (DAPI): blue. NC: normal control group, EC: 
experimental control; reperfusion 24 hr after MCAO injury, DHA: DHA treatment and reperfusion 24 hr after MCAO injury.
Fig. 8. Immunochemical image for confirmation of PSD-95 expression by DHA treatment. (A) Immunochemical images showed that PSD-95 positive 
cells (red) were few expressed in the EC group cortex. In DHA treatment group, PSD-95 expression was considerably increased in rat cortex compared 
to the EC group. (B) In DHA treatment group, PSD-95 positive cells were increased in rat striatum owing to DHA treatment. (C) The graph showed the 
percentage (%) of PSD-95 positive cells to compare the difference of PSD-95 fluorescence intensity. Differences were considered significant at **p<0.01 
(t -test via EC group). Scale bar=100 μm, PSD-95: postsynaptic density protein 95 (PSD-95); red, 4', 6-diamidino-2-phenylindole (DAPI): blue. NC: 
normal control group, EC: experimental control; reperfusion 24 hr after MCAO injury, DHA: DHA treatment and reperfusion 24 hr after MCAO injury.
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DHA treatment group, iNOS expression was decreased in both 
cortex (Fig. 7A) and striatum (Fig. 7B) compared to EC group. Fig. 
7C was shown that the significantly decreased fluorescent intensity 
of iNOS over 9 times in the DHA treatment group compared to 
EC group (Fig. 7C). Based on these results, we suggest that DHA 
may inhibit the expression of iNOS in ischemic brain and also 
block the expression of inflammatory mediators.
DHA prevents the damage of post synaptic plasticity 
following cerebral ischemia 
We performed immunohistochemistry using PSD-95 antibody 
at reperfusion 24 hr after MCAO injury to check whether DHA 
affect the postsynaptic plasticity’s damage following cerebral 
ischemia (Fig. 8). We observed strong PSD-95 immunoreactivity 
in the cortex of the NC group (Fig. 8A). However, PSD-95 positive 
cells were substantially decreased in the cortex at reperfusion 24 
hr after MCAO injury group (EC group) (Fig. 8A). In addition, 
it showed that strong expression of PSD-95 was observed in 
DHA treated rat cortex compared to 24 hr MCAO group (EC 
group). In striatum region, PSD-95 expression showed the same 
pattern as the cortex (Fig. 8B). Fig. 8C was significantly shown the 
increased fluorescent intensity of PSD-95 over 6 times in the DHA 
treatment group compared to EC group (Fig. 8C). Taken together, 
we speculate that DHA may improve the synaptic dysfunction in 
ischemic brain. 
DISCUSSION 
Ischemic stroke causes the blockage of cerebral blood vessels 
in the regions of brain, which can lead to human disability 
and death [36]. Subsequently, the blockage of blood vessels 
following stroke leads to diverse pathophysiologies including 
brain edema, neuronal loss, and cognitive dysfunction [37-40]. 
Cerebral cortex, hippocampus, and corpus striatum in the brain 
are the most vulnerable regions against oxidative stress and 
hypoxic injury induced by cerebral ischemia [41]. Many studies 
has reported that vitamin C among antioxidants is generally 
neuroprotective in response to brain ischemic injury [42-45]. 
Oral administration of AA to animal had demonstrated that it 
suppresses neuronal damage under cerebral ischemia-reperfusion 
[46]. Dehydroascorbic acid as AA’s oxidized form [15,18,19] 
has been reported that it has a neuroprotective role [47] and is 
easily transported to the brain by mediating glucose transporter 
1 (GLUT1) located in the endothelial cells of the BBB [48]. 
However, DHA did not fully be investigated in ischemic stroke 
animal model in spite of its advantages. We anticipated that DHA 
as an anti-oxidant may considerably affect on cerebral ischemia 
animal because it can rapidly pass through the brain than AA 
[25]. In present study, we investigated the neuroprotective effects 
of brain by DHA i.p administration in cerebral ischemia rat. First, 
we obtained the consequence that DHA treatment inhibits the 
brain edema formation in MCAO rat brain. Edema defined as an 
abnormal increase in brain water content is frequently observed 
in cerebral ischemia and also has a critical influence on morbidity 
and mortality [49]. Several studies reported that cerebral ischemia 
contributes to damage the integrity and permeability of the 
BBB [50,51]. Aquaporin (AQP) is the water channel protein 
that facilitates water transport through cell membranes [52,53]. 
Specifically AQP-1 is permeable only to water and is considered 
to participate in brain water homeostasis [54]. In addition, 
AQP 1 has been reported that it is involved in edema formation 
and cell death in the hippocampus following brain injury [55]. 
Following our results, we suggest that DHA may reduce osmotic 
water permeability following cerebral ischemia by inhibiting the 
expression of AQP-1. All BBB components have been reported 
to the association with the regulation of the BBB permeability 
including tight junctions of endothelial cells, glia cells [56-58]. The 
BBB is composed of the brain endothelial cells interconnected 
with transmembrane tight junction proteins such as claudin-5 [59] 
and regulates paracellular permeability [60,61]. In present study, 
our results indicated that claudin 5 as a tight junction protein in 
DHA treated MCAO rat brain was evidently preserved against 
ischemic injury. According to our results, DHA may protect the 
BBB integrity by preserving tight junction protein in response 
to ischemic injury. Cerebral ischemia induces the neurotoxic 
environment in brain and it could result in the severe neuronal 
cell damage, so we investigated the cell death marker such as Bax 
[62,63], caspase-3[64,65], and iNOS [66,67] in order to examine 
the protective effect of DHA against the neurotoxicity following 
ischemic stroke. In present study, DHA treatment reduced the 
expression of Bax and caspase-3 which is the marker of the 
mitochondrial cell death and iNOS in ischemic injured brain. 
Nitric oxide (NO) that causes neuronal cell death and exacerbates 
glutamate toxicity after cerebral ischemia [68] is synthesized by 
NO synthase such as iNOS [69]. Several studies demonstrated that 
inhibition of iNOS in cerebral ischemia improves neurological 
deficits and reduces infarct volume [70,71]. In consideration of 
Figure 1 result, our finding suggested that DHA attenuates the 
expression of iNOS and it may be linked to reduced infarct volume 
and improved cell death against hypoxic injury. Additionally, 
NO formed by iNOS has been reported the implicated in 
neurodegeneration [69]. Judging from our result regarding the 
reduced iNOS expression, we suggest the possibility of DHA 
regarding the improvement of cognitive function against ischemic 
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stroke although we did not check the production of NO and 
behavior test considering that AA improves the cognitive decline 
in Alzheimer’s disease [72]. As mentioned earlier, several studies 
demonstrated that DHA prevents cell death against ischemic 
injury [19,28-30]. However, previous studies have not yet been 
determined the effect of DHA on recovery of neuronal function in 
ischemia animal model. Therefore, we tried to examine the effect 
of DHA on neuronal function by measuring indirectly synaptic 
dysfunction in present study. In order to observe the effect of 
DHA on ischemia-induced synaptic connection alteration, we 
investigated the expression of PSD-95 protein in ischemic brain 
tissue. PSD-95 protein as a postsynaptic marker [73,74] is a 
member of the membrane-associated guanylate kinase family of 
synaptic molecules and is localized at excitatory synapses [75]. 
Postsynaptic densities (PSD) proteins are involved in regulation of 
synaptic function and in the transduction of synaptic signals to the 
postsynaptic cell [76-78]. Especially, PSD-95 has been implicated 
in the regulation of ion-channel function, synaptic activity, and 
intracellular signaling and finally cognitive impairment [79-81]. 
In addition, PSD-95 protein is implicated in promoting synapse 
stability and makes synaptic contacts more stable in neurons [75]. 
Recent studies suggested that the PSD-95 protein improves the 
neurophysiologic phenomenon after ischemic stroke involving 
MCAO [82,83]. Moreover, some researchers demonstrated that 
the decrease of PSD-95 protein immunoreactivity in the ischemic 
brain leads to a deficit of postsynaptic plasticity in the brain [84]. 
Several studies suggest that PSD-95’s reduction is associated 
with cognitive impairment [85-88]. Based on our results, our 
findings indicate that DHA induced the increase of PSD-95 
protein immunoreactivity in ischemic stroke brain and DHA may 
improve the ischemic-induced synaptic plasticity dysfunction. 
In addition, although we did not check the memory function 
related behavior test such as water maze, we carefully expect 
that DHA may improve the learning and memory dysfunction 
following cerebral ischemia by promoting the neuron’s synapse 
stability. Taken together, our findings suggest three points that 1) 
DHA is involved in the inhibition of AQP-1 expression and the 
preservation of claudin 5, ultimately resulting in the reduction 
of edema formation induced by cerebral ischemia, 2) DHA is 
associated with the decrease of Bax, cleaved caspase-3 and iNOS 
expression, ultimately resulting in the protection of cell death 
against neurotoxicity following cerebral ischemia, 3) DHA is 
linked to the preservation of PSD-95 protein expression, ultimately 
resulting in the improvement of neuron’s synaptic connection in 
cerebral ischemia. The present study has some limitations fully 
to prove the beneficial effect of DHA against ischemic injury. 
However, we suggest that this study is worthy in that it provide 
the need of the further study of DHA on ischemic stroke. Taken 
together, we propose that the DHA might be beneficial to alleviate 
clinical pathologies that occur after ischemic stroke.
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